Larimar Therapeutics
LRMR
61 hedge funds and large institutions have $114M invested in Larimar Therapeutics in 2018 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 8 closing their positions.
260% more capital inflows, than outflows
Capital inflows: $16.9M | Capital outflows: $4.69M
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
57% more call options, than puts
Call options by funds: $297K | Put options by funds: $189K
9% more funds holding
Funds holding: 56 → 61 (+5)
6.04% more ownership
Funds ownership: 49.49% → 55.54% (+6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.26M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.23M |
| 3 |
NC
Nexthera Capital
New York
|
+$1.63M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.41M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.42M |
| 2 |
Renaissance Technologies
New York
|
-$727K |
| 3 |
RA
Royce & Associates
New York
|
-$587K |
| 4 |
SIM
Spark Investment Management
New York
|
-$393K |
| 5 |
D.E. Shaw & Co
New York
|
-$276K |
LRMR Hedge Fund Activity: Q1 2018 in Review
61 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2018, worth a combined $114M — up 81% from $62.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LRMR positions and 8 closed out — a net gain of 5 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $3.26M. The largest seller was Deutsche Bank, cutting an estimated $1.42M.
- 61 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2018, up from 56 in Q4 2017.
- Funds reported $114M of Larimar Therapeutics stock for Q1 2018, up 81% quarter-over-quarter.
- 13 funds opened new Larimar Therapeutics positions in Q1 2018 and 8 closed out, a net change of +5 holders.
- The largest Larimar Therapeutics buyer in Q1 2018 was Balyasny Asset Management, an estimated $3.26M added.
- The largest Larimar Therapeutics seller in Q1 2018 was Deutsche Bank, an estimated $1.42M sold.
Based on aggregated 13F filings for Q1 2018.